Dr.HARIKA REGANI

Dr. SANTOSH G. HONAVAR, Dr. KAUSTUBH MULAY

Abstract

PurposeOutcomes of neoadjuvant intravenous chemotherapy (nIVC) in retinoblastoma (RB) group E eyes with clinical high-risk factors (CHRF) and factors predicting treatment failure.

Methods: Retrospective interventional consecutive case series of treatment-naive group E RB with CHRF managed by primary nIVC. Outcome measures were life, eye and vision salvage.

Among the 85 eyes of 79 patients managed by primary nIVC and focal consolidation, eye salvage was possible in 46 (52%). Secondary enucleation was necessary in 39 (45%), of which 6 (15%) showed histopathological risk factors and needed adjuvant chemotherapy. Possible risk factors for enucleation were not statistically significant. At a mean follow-up of 26+18 m, none had systemic metastasis and 19 (22%) had visual potential.

nIVC with appropriate focal consolidation can help eye salvage in about half of advanced Group E retinoblastoma with CHRF, which are otherwise considered standard indications for primary enucleation

Full Text